Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Long-Term Investments (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Long-Term Investments readings, the most recent being $37.6 million for Q4 2025.

  • Quarterly Long-Term Investments rose 966.83% to $37.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.6 million through Dec 2025, up 966.83% year-over-year, with the annual reading at $37.6 million for FY2025, 966.83% up from the prior year.
  • Long-Term Investments hit $37.6 million in Q4 2025 for Oramed Pharmaceuticals, up from $28.5 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $110.2 million in Q4 2023 and bottomed at $2000.0 in Q2 2021.
  • Average Long-Term Investments over 5 years is $13.9 million, with a median of $3.3 million recorded in 2021.
  • Peak annual rise in Long-Term Investments hit 1250700.0% in 2021, while the deepest fall reached 99.96% in 2021.
  • Oramed Pharmaceuticals' Long-Term Investments stood at $25.1 million in 2021, then plummeted by 89.23% to $2.7 million in 2022, then skyrocketed by 3981.04% to $110.2 million in 2023, then plummeted by 96.8% to $3.5 million in 2024, then skyrocketed by 966.83% to $37.6 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Long-Term Investments are $37.6 million (Q4 2025), $28.5 million (Q3 2025), and $3.5 million (Q2 2025).